کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
2120592 | 1546862 | 2006 | 13 صفحه PDF | دانلود رایگان |
![عکس صفحه اول مقاله: Microtubule-targeting agents in angiogenesis: Where do we stand? Microtubule-targeting agents in angiogenesis: Where do we stand?](/preview/png/2120592.png)
Angiogenesis is a key event of tumor progression and metastasis and hence a target for cancer chemotherapy. Therapeutic strategies focused on angiogenesis include the discovery of new, targeted anti-angiogenic agents and the re-evaluation of conventional anti-cancer drugs. Here, we review the most recent studies investigating the molecular and cellular mechanisms responsible for the anti-angiogenic activity of microtubule-targeting agents (MTAs). These agents include some of the most widely used and effective antitumor drugs that are also among the most anti-angiogenic. In addition, we summarize the latest results of pre-clinical and clinical studies involving MTAs administered at low metronomic doses and in anti-angiogenic combination strategies. Finally, we discuss the future development of these agents, their clinical potential and their limitations.
Journal: Drug Resistance Updates - Volume 9, Issues 1–2, February–April 2006, Pages 74–86